ArticleBMC infectious diseases2026
Multimodal non-surgical management of isolated tracheobronchial mucormycosis: a case series of 8 patients.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIsolated tracheobronchial mucormycosis (ITBM), a distinct subtype of pulmonary mucormycosis (PM), is a relatively rare but life-threatening infection. Here, we present our experience in the multimodal comprehensive treatment of ITBM.
methodsWe conducted a retrospective descriptive case series of ITBM patients at the Affiliated Hospital of Yunnan University from 2020 to 2023. Demographic characteristics, underlying diseases, clinical manifestations and details of treatment were collected.
resultsA total of 8 patients (3 males, 37.5%) with a mean age of 50.8 years were included. Diabetes was the most common risk factor and ITBM tended to involve the left main bronchus. All 8 patients started with intravenous antifungal therapy and transitioned to oral therapy once stable. Five (62.5%) received posaconazole injection, and six (75%) received posaconazole tablets. The average durations were 5.5 weeks for intravenous antifungal therapy, 17.4 weeks for oral therapy, and 22.9 weeks for total systemic therapy. Regarding topical antifungal therapy, a total of 7 (87.5%) patients were administered atomized inhalation of amphotericin B deoxycholate (AmBD) (2.5-5 mg/dose, twice daily), and the mean treatment time was 27.3 days. Similarly, seven (87.5%) patients received bronchoscopic instillation of AmBD (2.5-20 mg/dose, twice a week), with an average number of 5.6. All patients underwent bronchoscopic interventional treatment. The most frequently used interventional treatments were argon plasma coagulation (APC), cryoresection, and balloon dilatation. To maintain airway patency, 3 patients underwent tracheal silicone stent implantation. The main complication of interventional therapy was mild hemoptysis (50%). Finally, all patients achieved complete remission, with a mean time from diagnosis to complete remission of 5.3 months.
conclusionIn this case series of ITBM, a non-surgical multimodal management strategy was applied, and favorable clinical outcomes were observed during follow-up. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.